Jiangsu Hengrui Medicine
600276.SS
#475
Rank
$43.46 B
Marketcap
$6.81
Share price
-1.63%
Change (1 day)
4.66%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Revenue for Jiangsu Hengrui Medicine (600276.SS)

Revenue in 2024 (TTM): $3.63 Billion USD

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current revenue (TTM ) is $3.63 Billion USD. In 2023 the company made a revenue of $3.21 Billion USD an increase over the revenue in the year 2022 that were of $3.14 Billion USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) $3.63 B13.01%
2023 $3.21 B2.29%
2022 $3.14 B-21.35%
2021 $4.00 B-1.43%
2020 $4.06 B20.96%
2019 $3.35 B28.68%
2018 $2.60 B26.23%
2017 $2.06 B24.3%
2016 $1.66 B12.63%
2015 $1.47 B22.49%
2014 $1.20 B18.95%
2013 $1.01 B17.25%
2012 $0.86 B21.81%
2011 $0.70 B27.29%
2010 $0.55 B25.54%
2009 $0.44 B27.52%
2008 $0.34 B33.31%
2007 $0.26 B44.72%
2006 $0.18 B24.95%
2005 $0.14 B8.62%
2004 $0.13 B4.67%
2003 $0.12 B39.02%
2002 $91.36 M